This is a randomized, single blind, study. Males and females meeting inclusion criteria who have symptoms of mild COVID-19 and in whom a positive PCR result for SARS-CoV-2 is obtained may be enrolled to the study treatment within 72 hours of the positive PCR result. Eligible patients are those considered to be at high risk for COVID-19 disease progression. This includes patients ≥ 65 years of age or with any one or more of certain medical conditions including: cancer, COPD, cardiovascular disease, immunocompromised state resulting from solid organ transplant, obesity, sickle cell disease, history of smoking, and diabetes.
Eligible patients will be randomized, 1:2, to either placebo or STAT-205. Randomization will
be stratified by site. STAT-205 treatment will include an initial 5-day dosing period (period
1) of 22.5 mg QD, to be followed by a second dosing period (period 2) of 4.5 mg QD to
complete 30 days of dosing. Patients randomized to placebo will receive placebo QD. Blood
samples for pharmacokinetic analysis and measurement of inflammatory biomarkers will be
collected from patients on day 1, day 6, day 15 and day 30. Patients will be seen in the
clinic on days 1, 6, 15, and 30. Patients will be contacted via telephone for follow up on
day 60 and on. each post treatment day through Day 60. The telephone visit should occur at
approximately the same time each day. During the telephone visits, the presence and severity
of COVID-19 symptoms that were recorded at Baseline will be queried, and any new symptoms
will be recorded. During the daily telephone visits, patients will also be queried for any
adverse events.
Drug: STAT-205
naltrexone hydrochloride capsules 4.5 mg each
Inclusion Criteria:
1. Age >18 at the time of informed consent
2. Able to understand and provide informed consent in either English or Spanish
3. At high risk for COVID-19 disease progression by fulfilling at least ONE of the
following criteria at Screening:
1. Age ≥65 years
2. Has a diagnosis of chronic pulmonary disease requiring daily treatment (e.g.
COPD, chronic persistent asthma, cystic fibrosis, chronic bronchitis)
3. Has a diagnosis of chronic heart disease
4. Has a diagnosis of diabetes (type 1 or type 2) requiring oral therapy and/or
insulin therapy
5. Has hypertension requiring at least one oral medication for treatment
6. Has a body mass index (BMI) of ≥33 kg/m2
7. Has an immunocompromising disease (e.g. HIV infection with CD4 count < 200
cells/mm3)
8. Is immunocompromised due to daily treatment with ≥20 mg of prednisone or
equivalent
9. Has received a solid organ transplant
10. Has any chronic condition that, in the opinion of the investigator, places the
patient at increased risk for progression of COVID-19
4. Documentation of positive diagnostic test for SARS-CoV-2 (confirmed by PCR assay or
other approved diagnostic test) performed with a sample from nares or saliva,
collected within 7 days of the Screening visit.
5. Is symptomatic for COVID-19 for no more than 7 days prior to the Screening visit
6. Has a WHO Clinical Progression Scale (WHOb 2020) score of either '2' or '3' at
Screening and Randomization
7. Has at least one of the following symptoms at the Screening visit that are new in
onset, or if present by history, has worsened during the 7 days prior to Screening:
· fever, chills, myalgia, arthralgia, headache, fatigue, cough, sore throat, nasal
congestion, nausea, vomiting, diarrhea, anosmia or dysosmia, ageusia or dysgeusia
8. If female of child-bearing potential, must agree to use of 2 forms of contraception
from Screening to end of the study. Males must agree to use 2 forms of contraception
from screening to the end of the study if their partners are of childbearing
potential. Acceptable methods of birth control which must be used together are:
1. Oral or injectable contraceptive and condom, or
2. IUD and condom, or
3. Diaphragm with spermicide and condom.
9. Agrees to participate in all in-person visits and remote or home visits as required by
the protocol and to provide updated contact information, as necessary.
Exclusion Criteria:
1. Has a WHO Clinical Progression Scale (WHOb 2020) score of '4' or higher at Screening
or Enrollment
2. Previous hypersensitivity or allergic reactions to naltrexone
3. Women who are pregnant or lactating or expecting to become pregnant
4. Drugs of abuse screen positive for opiates
5. Patients with history of moderate to severe renal impairment (estimated creatinine
clearance < 50 mL/min) or hepatic impairment (Child-Pugh C)
6. Serum ALT or AST value > 3 times the ULN at Screening
7. Serum creatinine value > 2 times the ULN at Screening, or requires renal dialysis
8. Hematology results at Screening showing any one of the following: WBC <2000 cells/mm3
or platelet count <100,000 cells/mm3 or hemoglobin <8.5 Gm/dL
9. Currently receiving chronic daily opioid therapy
10. Use of tocilizumab or other immunomodulator therapy directed to treatment or
prevention of COVID-19
11. History of active substance abuse within the 2 years prior to Screening
12. Participation in another clinical trial investigating a treatment for COVID-19
13. Currently hospitalized or under immediate consideration for hospitalization (for any
medical reason) at the Screening visit
14. At Screening, has new onset of dyspnea (shortness of breath) or, if previously
diagnosed with a chronic lung condition, the severity of dyspnea has increased over
patient's historical baseline condition (increased dyspnea should be present
continually and not intermittent)
15. Measurement of oxygen saturation at Screening is < 94% on ambient room air
16. Shares a household with a patient currently enrolled in this protocol
17. Patients who refuse biomarker blood draws
Loma Linda University
Loma Linda, California, United States
Clinical Research Center of Florida
Pompano Beach, Florida, United States
Dawn Louro
1-888-629-4155 - 147
dawn.louro@staterbiopharma.com